工程化CAR-T衍生外泌体共递送miR-145和细胞毒性蛋白用于靶向实体瘤治疗

核心信息

• 论文英文标题: Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy
• 期刊: J Extracell Vesicles
• 发表年份: 2026
• DOI: 10.1002/jev2.70245
• PMID/PMCID: 41806322; PMC12974908

研究概览

This study proposes a synergistic nanotherapeutic paradigm integrating antigen-specific killing and gene regulatory modulation, offering a promising direction for solid tumour treatment with improved safety and efficacy. Here, we develop a bioactive, cell-free therapeutic platform by engineering exosomes derived from B7-H3-targeted CAR-T cells and loading them with miR-145 (Name this exosome as exo-CT-145).

核心发现

Chimeric antigen receptor T cell (CAR-T) therapy has demonstrated remarkable efficacy in haematologic malignancies but remains constrained in solid tumours due to limited tumour penetration, immunosuppressive microenvironments and the risk of cytokine release syndrome (CRS).

Here, we develop a bioactive, cell-free therapeutic platform by engineering exosomes derived from B7-H3-targeted CAR-T cells and loading them with miR-145 (Name this exosome as exo-CT-145).

The exosomes retain CAR-specific surface markers and cytotoxic payloads (perforin and granzyme), MiR-145 is expressed at low levels in various tumours and can inhibit the occurrence and development of tumours through multiple pathways.

Exo-CT-145 significantly inhibited proliferation, migration, and Epithelial Mesenchymal Transition (EMT) of oesophageal squamous cell carcinoma (ESCC) cells and induced apoptosis in vitro.

Echo Biotech 角色

Exoload负载miRNA mimics

关联平台: Echosome®, Research Reagents & Tools

关联服务与能力: Small RNA / Cargo Loading, Research Reagent / Product Supply

关联产品或试剂: ExoLoad® Nucleic Acid Loading Kit

参考文献

原始论文: Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy Journal of extracellular vesicles. 2026. DOI: 10.1002/jev2.70245. PMID/PMCID: 41806322; PMC12974908.